Low-profile startup stakes its claim to Sanofi's siRNA platform in wake of setbacks

A biotech in China reports today that it will be scooping up a string of preclinical siRNA programs from Sanofi as the multinational player laterals a development platform to the Lilly-backed group in Shanghai.